{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:15:00Z","timestamp":1788052500786,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019306","name":"Chandigarh University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119178","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:54:30Z","timestamp":1784645670000},"page":"119178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Small molecule allosteric modulators of mutant EGFR for non-small cell lung cancer therapy: An insight into design strategies and structure activity relationships"],"prefix":"10.1016","volume":"318","author":[{"given":"Sandipan","family":"Dash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Shehensha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Meduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa Mohan","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-9143","authenticated-orcid":false,"given":"Arghya Kusum","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subas Chandra","family":"Dinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119178_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119178_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib3","article-title":"Advances in the pathogenesis and therapeutic strategies of non-small cell lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119178_bib4","article-title":"Emerging trends in lung cancer incidence and risk factors: a comprehensive analysis","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiology"},{"key":"10.1016\/j.ejmech.2026.119178_bib5","first-page":"1","article-title":"The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis","author":"Ji","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119178_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as a therapeutic target in lung cancer","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.119178_bib7","first-page":"289","article-title":"Immunotherapy in lung cancer: current status and future directions","volume":"4","author":"Dong","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.ejmech.2026.119178_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119178_bib9","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Mechanisms of resistance to targeted therapies in non-small cell lung cancer","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119178_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/cancers11070923","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"11","author":"Santoni-Rugiu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119178_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s12094-019-02075-1","article-title":"Overcoming resistance to EGFR inhibitors in NSCLC: a review of current progress and future perspectives","volume":"21","author":"Gao","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to anti-EGFR therapy in colorectal cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119178_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"The role of the oncology pharmacist in managing EGFR TKI-associated adverse events","volume":"26","author":"Harvey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2026.119178_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of fourth-generation EGFR tyrosine kinase inhibitors for resistant NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"The role of EGFR in cancer metastasis","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119178_bib17","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"Update on the EGFR family: signaling and cancer progression","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119178_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119178_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcdb.2018.05.011","article-title":"The EGFR pathway: a model for regeneration and homeostasis","volume":"87","author":"Barber\u00e1n","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.119178_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2026.119178_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of EGFR inhibitor resistance in non-small cell lung cancer","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Emerging therapeutic strategies to overcome drug resistance in EGFR-mutant lung cancer","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2026.119178_bib23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119178_bib25","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119178_bib26","first-page":"10","article-title":"T790M and acquired resistance of EGFR TKI: a literature review","volume":"3","author":"Ma","year":"2011","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejmech.2026.119178_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040315","article-title":"BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations","volume":"4","author":"Costa","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2026.119178_bib28","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-07-0070","article-title":"EGFR mutation and response in a patient with metastatic non-small-cell lung cancer","volume":"13","author":"Toyooka","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib29","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1200\/jco.2008.26.15_suppl.8056","article-title":"Acquired resistance to gefitinib in EGFR-mutant lung cancer","volume":"26","author":"Bean","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10637-014-0146-x","article-title":"Clinical experience with afatinib in patients with advanced non-small-cell lung cancer","volume":"32","author":"Woo","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119178_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000365325","article-title":"Osimertinib in a patient with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer","volume":"7","author":"Khan","year":"2014","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib32","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-18-0198","article-title":"May T790M change the treatment strategy in EGFR-mutant NSCLC?","volume":"24","author":"Cappuzzo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10120-014-0394-7","article-title":"HER2 amplification and sensitivity to trastuzumab in gastric cancer","volume":"18","author":"Nishida","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejmech.2026.119178_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119178_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3480","article-title":"An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models","volume":"15","author":"Xia","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3892\/ijo.2014.2538","article-title":"L858R EGFR mutation status correlates with runt-related transcription factor 3 expression in non-small-cell lung cancer","volume":"45","author":"Nakata","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119178_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s43440-020-00131-0","article-title":"Discovery of dual inhibitors of EGFR and HER2","volume":"72","author":"Maity","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2026.119178_bib38","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1074\/jbc.M115.660498","article-title":"Signaling through the phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in EGFR-mutated lung adenocarcinoma","volume":"290","author":"Makinoshima","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","article-title":"The EGFRvIII transcriptome in glioblastoma: a review of its molecular mechanisms","volume":"371","author":"Mitchell","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2026.119178_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pharep.2017.10.005","article-title":"The effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of erlotinib","volume":"70","author":"Zhang","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2026.119178_bib41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/cancers11081094","article-title":"Targeting the allosteric site of EGFR: a novel series of indolyl-pyrimidine derivatives","volume":"11","author":"Iradyan","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119178_bib42","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/acsmedchemlett.9b00381","article-title":"Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors","volume":"10","author":"De Clercq","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119178_bib43","article-title":"In silico study of natural compounds as potential inhibitors of EGFR T790M\/L858R","volume":"7","author":"Nurisyah","year":"2024","journal-title":"Current Research in Structural Biology"},{"key":"10.1016\/j.ejmech.2026.119178_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101329","article-title":"In silico and in vitro evaluation of novel carbothioamide-based and heterocyclic derivatives of 4-(tert-butyl)-3-methoxybenzoic acid as EGFR tyrosine kinase allosteric site inhibitors","volume":"7","author":"Al-Rubaye","year":"2024","journal-title":"Results Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119178_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14756366.2022.2145284","article-title":"Structure-activity exploration of a small-molecule allosteric inhibitor of T790M\/L858R double mutant EGFR","volume":"38","author":"Foschi","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1021\/acsmedchemlett.8b00564","article-title":"Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFRL858R\/T790M\/C797S","volume":"10","author":"Li","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119178_bib47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119178_bib48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119178_bib49","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3390\/ijms25031887","article-title":"Identification of new EGFR inhibitors by structure-based virtual screening and biological evaluation","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119178_bib50","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1080\/07391102.2021.1874530","article-title":"Molecular docking and dynamics studies of novel EGFR inhibitors as potential anticancer agents","volume":"40","author":"Wu","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.119178_bib51","doi-asserted-by":"crossref","first-page":"21438","DOI":"10.1021\/acs.jmedchem.4c02311","article-title":"Bivalent EGFR kinase inhibitors: optimization of linker and dimerization motif for enhanced cellular potency","volume":"67","author":"Wittlinger","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib52","series-title":"Linking ATP and Allosteric Sites to Achieve Superadditive Binding with Bivalent EGFR Kinase Inhibitors","author":"Heppner","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119178_bib53","article-title":"Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119178_bib54","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1021\/acs.jmedchem.1c00848","article-title":"Design of a \u201ctwo-in-one\u201d mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites","volume":"65","author":"Wittlinger","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib55","first-page":"6646","article-title":"In silico screening of natural compounds as potential inhibitors of EGFR T790M mutant","volume":"13","author":"Saini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119178_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117534","article-title":"Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites","volume":"96","author":"Fan","year":"2023","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.ejmech.2026.119178_bib57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jccs.202400084","article-title":"Synthesis and anticancer evaluation of novel hydrazone derivatives as EGFR inhibitors","volume":"71","author":"Shinde","year":"2024","journal-title":"J. Chin. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119178_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114889","article-title":"Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: in vitro screening and ADME predictions","volume":"245","author":"Kardile","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib59","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1021\/acs.jmedchem.2c00893","article-title":"Discovery of a novel, potent, and selective EGFR allosteric inhibitor, JBJ-09-063","volume":"65","author":"Obst-Sander","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119178_bib60","doi-asserted-by":"crossref","first-page":"14589","DOI":"10.1002\/ange.202003500","article-title":"Mutant-Selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"132","author":"Jang","year":"2020","journal-title":"Angew. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:17:58Z","timestamp":1788049078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":60,"alternative-id":["S0223523426006239"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119178","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule allosteric modulators of mutant EGFR for non-small cell lung cancer therapy: An insight into design strategies and structure activity relationships","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119178"}}